Sarepta Therapeutics (SRPT) Receivables - Other (2011 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Receivables - Other of $136.4 million for Q1 2026, up 147.1% year-over-year from $55.2 million in Q1 2025, and up 31.03% quarter-over-quarter from $104.1 million in Q4 2025.
Sarepta Therapeutics (SRPT) Receivables - Other (2011 - 2026) Analysis & Trends
Sarepta Therapeutics' Receivables - Other history runs 16 years deep, the most recent figure standing at $136.4 million for Q1 2026.
- In Q1 2026, Receivables - Other rose 147.1% year-over-year to $136.4 million; the TTM figure through Mar 2026 stood at $136.4 million (up 147.1% YoY), while the FY2025 annual figure was $104.1 million, up 200.87% from the prior year.
- Receivables - Other for Q1 2026 stood at $136.4 million, up from $104.1 million in the prior quarter.
- The five-year high for Receivables - Other was $136.4 million in Q1 2026, with the low at $3.3 million in Q4 2022.
- The 5-year median for Receivables - Other is $34.6 million (2024), against an average of $51.4 million.
- The sharpest annual moves came in 2022 and 2024: Receivables - Other surged 41287.5% in 2022, then slumped 51.45% in 2024.
- Sarepta Therapeutics' Receivables - Other stood at $3.3 million in 2022, then jumped by 800.03% to $29.8 million in 2023, then rose by 16.11% to $34.6 million in 2024, then soared by 200.87% to $104.1 million in 2025, then jumped by 31.03% to $136.4 million in 2026.
- Business Quant data shows SRPT's Receivables - Other at $136.4 million in Q1 2026, $104.1 million in Q4 2025, and $128.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.00 Mn |
| Jun 30, 2026 | 45.00 Mn |
| Mar 31, 2026 | 136.40 Mn |
| Mar 31, 2026 | 136.40 Mn |
| Dec 31, 2025 | 104.10 Mn |
| Dec 31, 2025 | 104.10 Mn |
| Sep 30, 2025 | 128.70 Mn |
| Sep 30, 2025 | 128.70 Mn |
| Jun 30, 2025 | 73.30 Mn |
| Jun 30, 2025 | 73.30 Mn |
| Mar 31, 2025 | 55.20 Mn |
| Mar 31, 2025 | 55.20 Mn |
| Dec 31, 2024 | 34.60 Mn |
| Dec 31, 2024 | 34.60 Mn |
| Sep 30, 2024 | 66.40 Mn |
| Sep 30, 2024 | 66.40 Mn |
| Jun 30, 2024 | 19.90 Mn |
| Jun 30, 2024 | 19.90 Mn |
| Mar 31, 2024 | 30.10 Mn |
| Mar 31, 2024 | 30.10 Mn |